# Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101

Source: https://onco.cc/trials/nct07168226/  
OnCo record `nct07168226` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Active Comparator in advanced solid tumours, run by MetaFines, now recruiting.

## Summary

Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101 is a phase 2 interventional study registered as NCT07168226 by MetaFines, with 135 participants planned, started 2026-05-08 and due to reach its primary completion in 2028-04-30. Interventions recorded: Active Comparator, ASCA101 24.32mg/kg, ASCA101 32.43mg/kg and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07168226
- Phase: 2
- Setting: A Multi-center, Randomized, Phase 2 Clinical Trial to Exploratively Evaluate the Efficacy and Safety of ASCA101 for the Treatment of Cachexia in Patients With Solid Tumor
- Sponsor: MetaFines
- Enrolled: 135

## Sources

- ClinicalTrials.gov NCT07168226: https://clinicaltrials.gov/study/NCT07168226

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07168226.json